Filters
Repeatability, reproducibility, and observer variability of body composition assessment with single-slice lumbar MRI
Nowak, M., et al. (2025)
Discover imaging
Read Summary ▾
Single-slice MRI at the L3 vertebral level provides accurate and reproducible area measurements of fat and muscle across diverse body types, multiple MRI scanner field strengths, and manufacturers. The measurements are consistent between trained analysts and experienced radiologists.
Quantitative liver function imaging and whole genome sequencing – Effective modalities for a new era in personalised decision-making for operable colorectal liver metastases?
Welsh F., et al. (2025)
HPB
Read Summary ▾
In the Precision1 trial, preoperative mpMRI and whole-genome sequencing (WGS) informed personalized surgery for operable colorectal liver metastases. mpMRI frequently influenced surgical plans (e.g., embolization, parenchymal-sparing or more extensive resections, weight management). WGS provided therapeutic and prognostic insights, supporting tailored, multidisciplinary decision-making.
Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD
Moolla, A., et al. (2025)
JHEP Reports
Read Summary ▾
In this randomised control trial in people with MASLD without diabetes, LiverMultiScan monitored improvements in liver fat and liver disease activity following 12-week treatment with liraglutide, and the subsequent rebound after cessation. A low-calorie diet of similar duration achieved equivalent improvements.
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
Harrison, S., et al. (2025)
Journal of Hepatology
Read Summary ▾
In a 12-week MASLD trial, pemvidutide (a GLP-1/glucagon dual agonist) markedly reduced liver fat and improved cT1 versus placebo, alongside improvements in body weight and liver enzymes. A high proportion achieved clinically meaningful cT1 reductions. Treatment was well tolerated without serious adverse events, supporting pemvidutide as a promising therapy.
MRI-serum–based score accurately identifies patients undergoing liver transplant without rejection avoiding the need for liver biopsy: A multisite European study
Schaapman, J., et al. (2025)
Liver Transplantation
Read Summary ▾
Using multiparametric MRI metrics alongside routine blood markers supports identification of liver transplant patients without rejection, enabling many to avoid a liver biopsy. Findings support a practical, non-invasive pathway to monitor graft health and reduce unnecessary invasive procedures.
Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial
Shumbayawonda E., et al. (2025)
Communications Medicine
Read Summary ▾
Incorporating LiverMultiScan into the MASLD diagnostic pathway is cost-effective, significantly reduces the number of specialist appointments, patient assessments, and rate of diagnosis without increasing other liver-related health care resource use. cT1 also correctly classified 50% of patients without MASH with fibrosis who could avoid biopsy. Standardized adoption of LiverMultiScan can streamline clinical pathways, lower costs, and improve long-term management.
Standardized pancreatic MRI-T1 measurement methods: comparison between manual measurement and a semi-automated pipeline with automatic quality control
Bagur, A., et al. (2025)
British Journal of Radiology
Read Summary ▾
Manual srT1, a standardized biomarker of pancreatic fibro-inflammation, showed excellent intra- and inter-observer reproducibility and strong scan–rescan reliability. A semi-automated workflow further improved scan–rescan agreement.
Liver fibro-inflammation in psoriatic arthritis with MASLD improved by anti-IL-17 treatment: a clinical case
James, L., et al. (2025)
Rheumatology
Read Summary ▾
A 37-year-old woman with psoriatic arthritis and undiagnosed liver disease showed significant reversal of liver fibro-inflammation after 6 months of IL-17A inhibitor (secukinumab) treatment. Quantitative mpMRI and blood tests confirmed improved liver health, suggesting biologic disease-modifying antirheumatic drugs may benefit coexisting metabolic liver disease and psoriatic disease.
Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort
Chen, V., et al. (2025)
Journal of Hepatology
Read Summary ▾
Poor diet quality and specific genetic alleles are associated with steatotic liver disease. Diet has a much greater impact on hepatic steatosis in those at higher genetic risk, affecting both liver fat content and cT1 (a measure of fibrosis and inflammation). Thus, dietary interventions may yield greater benefit in genetically susceptible groups.
Change in cT1 following interventions in MASLD: A systematic review and meta-analysis
Andersson, A., et al. (2025)
Clinical Gastroenterology and Hepatology
Read Summary ▾
Treatment interventions in MASLD significantly reduce liver cT1 by an average of 57 ms, indicating improved liver health. Fibroblast growth factor analogues, GLP-1 receptor agonists, and FXR agonists showed notable effects, while placebo showed no change. These results inform study design, supporting cT1 as a useful non-invasive treatment response marker.
Accuracy, repeatability, reproducibility and reference ranges of primary sclerosing cholangitis specific biomarkers from quantitative MRCP
Harisinghani, M., et al. (2025)
Abdominal Radiology
Read Summary ▾
Quantitative MRCP-derived metrics showed high accuracy, repeatability, and reproducibility across scanners, effectively distinguishing healthy individuals from PSC patients. These findings support the use of MRCP+ metrics for assessing biliary health and their suitability for multi-centre clinical trials and longitudinal monitoring in liver disease
Severe Dietary Energy Restriction for Compensated Cirrhosis Due to Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Randomised Controlled Trial
Koutoukidis, D. A., et al. (2025)
Journal of Cachexia, Sarcopenia and Muscle
Read Summary ▾
Severe energy restriction safely induced significant weight loss and reduced liver fat in patients with compensated cirrhosis due to MASLD (CC-MASLD). No adverse effects or liver deterioration were observed, while both MRI-PDFF and cT1 were significantly reduced. These promising results support further research into diet-based interventions for CC-MASLD management
Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis
Sanyal, A. J., et al. (2025)
New England Journal of Medicine
Read Summary ▾
Once-weekly semaglutide significantly improved liver histology in patients with MASH and fibrosis, compared to placebo. It also achieved substantial weight loss, although gastrointestinal side effects were more common. Semaglutide improved noninvasive liver markers, though the high placebo response underscores the need for more precise monitoring tools.
Quantitative MRCP metrics as imaging biomarkers to differentiate benign from malignant bile duct obstructions
Eurboonyanun, K., et al. (2025)
Frontiers in Oncology
Read Summary ▾
Quantitative MRCP metrics, especially total biliary tree volume, effectively distinguished malignant from benign biliary obstructions. A volume ≥25 ml predicted malignancy with good accuracy (AUC 0.79). These findings support MRCP+ as a non-invasive, contrast-free tool for identifying cholangiocarcinoma, potentially aiding earlier diagnosis and improving patient outcomes.
Cardiac and liver impairment on multi-organ MRI and risk of major adverse cardiovascular and liver events
Jackson E., et al. (2025)
Nature Medicine
Read Summary ▾
Among UK Biobank participants with MRI, elevated liver cT1 and reduced left-ventricular ejection fraction independently—or in combination—predicted cardiovascular and liver events and all-cause mortality. Cardiac and hepatic impairment often coexisted, supporting multi-organ MRI as a tool for integrated risk stratification and prevention pathways spanning heart and liver disease.
Multiparametric magnetic resonance imaging may improve detection of patients with at-risk MASH: Real world experience in hepatology clinics
Phipps, M. M., et al. (2025)
Digestive and Liver Disease
Read Summary ▾
Multiparametric MRI detected increased risk of MASH or advanced fibrosis in over half of MASLD patients classified as low risk by FIB-4. Early use of multiparametric MRI could identify at-risk patients, particularly women and those with diabetes, enabling timely intervention and better disease management compared to current guideline-based risk stratification.
TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial
Noureddin, M., et al. (2025)
Nature Medicine
Read Summary ▾
TERN-501, a THRβ agonist, significantly reduced liver fat in a dose-dependent manner over 12 weeks in patients with MASH. Compared to placebo, MRI-PDFF and cT1 reductions were substantial, and significantly more participants receiving TERN-501 achieved a clinically significant change in cT1 by 6 weeks.
High prevalence of MASLD in psoriasis and psoriatic arthritis assessed with multiparametric magnetic resonance imaging
James, L., et al. (2025)
Rheumatology
Read Summary ▾
Psoriatic disease (PsD) patients show a high prevalence of metabolic liver conditions (44% with MASLD and 22% with MASH) despite normal blood tests. Rates exceed those in matched controls and occur regardless of methotrexate use, highlighting the need for routine liver screening in PsD management e.g. by multiparametric MRI
Practical applications of AI in body imaging
Mervak, B. M., et al (2025)
Abdominal Radiology
Read Summary ▾
AI and deep learning are reshaping radiology, offering improved accuracy, efficiency, and automation. This review highlights FDA-cleared AI tools for abdominopelvic imaging available in the U.S. by late 2024, explores their clinical value, and outlines opportunities for future innovation
Left atrial volume quantification by transthoracic echocardiography versus cardiovascular magnetic resonance imaging: a systematic review and meta-analysis
Mahmod, M., et al. (2025)
The International Journal of Cardiovascular Imaging.
Read Summary ▾
Left atrial volume (LAV) is key in diagnosing heart failure with preserved ejection fraction. Compared to cardiovascular magnetic resonance (CMR), transthoracic echocardiography frequently fails or underestimates LAV, misclassifying enlargement in 38% of cases. CMR remains the more accurate gold standard for LAV assessment
Automatic Couinaud segmentation using AI and pictorial representation based landmarking
Nunez, L., et al. (2025)
Abdominal Radiology
Read Summary ▾
This study presents a deep learning framework for accurate, personalized Couinaud liver segment localization using MRI data. It outperforms existing methods in landmark placement and segment volume estimation, is explainable, adaptable across imaging types, and scalable, potentially improving liver surgery planning and clinical workflow efficiency
Exploring the role of MRCP+ for enhancing detection of high-grade strictures in primary sclerosing cholangitis
Franklin, J., et al. (2025)
Journal of Clinical Medicine
Read Summary ▾
Adding quantitative MRCP+ metrics to standard MRCP improves radiologists’ confidence and agreement in detecting high-grade strictures in primary sclerosing cholangitis patients. MRCP+ reduces variability, enhances diagnostic reliability, and may help standardize assessments, potentially improving patient management and treatment decisions
Real-world assessment of liver corrected T1 and magnetic resonance elastography in predicting liver disease progression.
Corey K. E., et al (2025)
Liver International
Read Summary ▾
Guidelines prioritise early detection of chronic liver disease progression risk. To avoid biopsy, NITs have become part of standard‐of‐care. Across etiologies, patients with low fibrosis risk by MRE but high disease activity by cT1 have ~threefold higher progression, showing cT1 flags risk earlier than stiffness alone. Integrating cT1 into care pathways improves stratification and proactive management without biopsy.
Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States
Hancock, M., et al (2025)
Journal of Medical Economics
Read Summary ▾
cT1-based pathway to assign suspected MASH patients to resmetirom and monitor response delivered the lowest per-patient costs in the VA: $7,022 (cT1) vs $7,268 (biopsy) vs $28,509 (VCTE), in the base-case and scenario analyses. Choose cT1: more efficient treatment allocation, better care, lower spend
Automated volumetric MRI quantification of body fat and skeletal muscle in the UK Biobank: technical validation against expert manual segmentations and comparison with single-slice techniques
Nowak, M., et al. (2025)
Abdominal Radiology
Read Summary ▾
Automated volumetric MRI delivers gold-standard fat and muscle quantification at scale, validated against expert manual segmentations. Lumbar single-slice measurements are strongly correlated with volumes, enabling fast routine assessments. Interchangeable, vendor-neutral methods standardize body composition endpoints for clinics and trials—enabling confident monitoring and scalable, trial-ready biomarkers.
Reliable monitoring of patients with MASLD using imaging: a systematic literature review and meta-analysis on measurement repeatability
Ndaa M., et al (2025)
Endocrine Practice
Read Summary ▾
A systematic review and meta-analysis of 19 studies including 1040 patient data have shown that cT1 and liver fat content (LFC) are significantly more reliable in detecting change in liver health in people living with MASLD-MASH, compared to liver stiffness NITs. Liver stiffness measurements are less suited to monitoring individual patients.
Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease
Mak, A. L., et al. (2024)
JHEP Reports
Read Summary ▾
The study included pancreatic T1/PDFF and hepatic cT1/PDFF measures to assess pancreas–liver relationships in MASLD. Intrapancreatic fat deposition was not associated with hepatic steatosis. Pancreatic T1 was increased across disease stages, consistent with pancreatic inflammation in individuals with impaired glucose homeostasis.
Novel multimetric MRI detects improved future liver remnant quality post-dual vein embolization
Sundaravadanan, S., et al. (2024)
HPB
Read Summary ▾
Hepatica showed a significant improvement in future liver remnant (FLR) health, measured by cT1 and PDFF, in 10 consecutive patients with liver metastasis and insufficient FLR after undergoing dual vein embolization in the Precision1 clinical trial. “This is a significant advance in our understanding of how to prevent liver failure in patients undergoing major liver surgery.”
Quantitative digital pathology enables automated and quantitative assessment of inflammatory activity in patients with autoimmune hepatitis
Socha, P., et al. (2024)
Journal of Pathology Informatics
Read Summary ▾
Quantitative digital pathology objectively measures inflammatory activity in autoimmune hepatitis, showing strong concordance with consensus histological assessment. By quantifying inflamed tissue area and inflammatory foci density on whole-slide images, the approach enables automated assessment, better stratification, and identification of patients with more advanced inflammatory disease.
Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study
Trivedi, P. J, et al. (2024)
AP&T
Read Summary ▾
MRCP+ metrics differentiated between AIH, PBC and PSC, highlighting its potential as an adjunctive diagnostic tool. In PSC, baseline strictures and bile-duct metrics correlated with Modified Amsterdam Score, transient elastography, and ALP. Over one year, strictures increased in more than half of patients, while biochemistry, elastography, or Amsterdam Score showed no change.
Quantitative imaging reveals steatosis and fibro-inflammation in multiple organs in people with type 2 diabetes: a real-world study
Diamond, C., et al. (2024)
Diabetes
Read Summary ▾
The first comprehensive analysis of multi-organ steatosis and fibro-inflammation in people living with obesity and type 2 diabetes receiving routine hospital care. Those on weight loss treatments saw improvements in organ health that did not occur in patients on metformin, highlighting the measurable and visible impact of weight-loss therapies in real-world patients.
Multi-organ abnormalities assessed by a single MRI scan in individuals with blood cancer
Reed, S., et al. (2024)
European J Internal Medicine
Read Summary ▾
CoverScan efficiently detects multi-organ abnormalities in patients with blood cancer, enabling more personalised treatment and potentially better outcomes. Compared with healthy controls, multi-organ impairment was more frequent, predominantly affecting the spleen and kidneys.
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Tacke, F., et al. (2024)
Journal of Hepatology
Read Summary ▾
Guidelines note an indirect MRI method for MASH and fibrosis diagnostics, LiverMultiScan, that can be performed on standard scanners without an elastography unit. By generating iron-corrected T1 (cT1) maps from T1 and T2* data, it estimates extracellular volume, reflecting inflammatory activity and fibrosis, aiding MASH and fibrosis assessment.
Tirzepatide for Metabolic Dysfunction – Associated Steatohepatitis with Liver Fibrosis
Loomba, R., et al. (2024)
NEJM
Read Summary ▾
Over 52 weeks, weekly tirzepatide significantly increased MASH resolution without fibrosis worsening in biopsy-confirmed MASH with F2–F3 fibrosis. It also showed improvement of at least one fibrosis stage without worsening MASH. cT1 was significantly reduced in the treatment group compared to placebo, showing a dose-dependent reduction.
The effectiveness of magnetic resonance imaging (MRI) iron corrected T1 in monitoring metabolic dysfunction-associated steatohepatitis in obesity following bariatric surgery and lifestyle modification: a prospective cohort study
Chiyanika, C., et al. (2024)
Quantitative Imaging in Medicine and Surgery
Read Summary ▾
Among adults with obesity and MASLD, MRI biomarkers, including cT1, assessed liver health and identified MASH with high accuracy. Bariatric surgery achieved greater reductions in cT1 and PDFF than lifestyle modification, indicating superior improvement in liver health and supporting cT1 for monitoring treatment response.
Risk of Type 2 Diabetes, Metabolic Dysfunction Associated Steatotic Liver Disease and Cardiovascular Disease in People Living with Polycystic Ovary Syndrome According to Disease Phenotype: An Analysis of Prospective Cohort and Multi-Organ Imaging Data from the UK Biobank.
Henney, A. E, et al. (2024)
The Lancet
Read Summary ▾
In UK Biobank, women with PCOS had greater prevalence and incidence of type 2 diabetes, steatotic liver disease, and all-cause cardiovascular disease. Liver MRI showed more severe steatosis and higher fibroinflammation by cT1. These comorbidities are increased in older PCOS patients with a disease phenotype-specific pattern.
Assessing the performance of AI‐assisted technicians in liver segmentation, Couinaud division, and lesion detection: a pilot study
Nunez, L., et al. (2024)
Hepatobiliary
Read Summary ▾
An AI-assisted workflow allowed non-radiologists to perform liver delineation, Couinaud segmentation, and lesion detection on MRI with accuracy comparable to radiologists, reducing workload. Agreement on whole-liver volume and segment measurements was high, and all lesions identified by radiologists were found; non-radiologists also flagged additional lesions confirmed by external adjudicator radiologists.
T1 Mapping of the Abdomen, From the AJR “How We Do It” Special Series
Serai, S. D., et al. (2024)
American Journal of Roentgenology
Read Summary ▾
Technical overview of quantitative MRI advancements including abdominal T1 mapping of liver, pancreas, and kidneys. T1 mapping produces color-coded maps that highlight changes related to inflammation and fibrosis, aiding in diagnoses like liver fibro-inflammation. Standardized methods are emphasized to improve diagnostic accuracy and enable reliable longitudinal assessment.
Feasibility of using contrast-free quantitative magnetic resonance imaging for liver sparing stereotactic ablative body radiotherapy
Brewster, F., et al. (2024)
Clinical and Translational Radiation Oncology
Read Summary ▾
In liver metastases, functional liver volumes automatically segmented using cT1 maps were used to create liver-sparing plans, which significantly reduced the functional liver mean dose versus standard planning. This first demonstration of cT1-guided stereotactic ablative radiotherapy suggests a route to spare healthy liver, though validation in liver cancer cohorts is required.
The Glutamate-Serine-Glycine Index as a Biomarker to Monitor the Effects of Bariatric Surgery on Non-alcoholic Fatty Liver Disease
Tan., et al. (2024)
Journal of the ASEAN Federation of Endocrine Societies
Read Summary ▾
In a longitudinal bariatric surgery case series, liver fat (PDFF), cT1, and the glutamate–serine–glycine (GSG) index all showed reductions postoperatively. These findings support integrating blood and imaging biomarkers to monitor improvement and guide interventions.
Decreases in cT1 and liver fat content reflect histological improvement induced by therapies in MASH: a multicentre pooled coho rt analysis.
Alkhouri, N., et al. (2024)
Journal of Hepatology
Read Summary ▾
Across three multicentre trials, changes in cT1 and PDFF predicted histologic response to MASH therapy. A reduction in cT1 of -80 ms was associated with a 5-fold increase in the odds of achieving resolution of steatohepatitis, a 30% PDFF reduction had roughly fourfold higher odds, while the optimal threshold of -58% had sevenfold higher odds.
Quantitative MRI for monitoring metabolic dysfunction associated steatotic liver disease: A test-retest repeatability study
Beyer, C., et al. (2024)
JMRI
Read Summary ▾
This study demonstrates the accuracy and reproducibility of LiverMultiScan metrics (cT1 and PDFF) in patients with MASH and MASLD. The results quantify the minimal detectable (absolute) changes in cT1 (32 ms) and liver fat fraction (0.6%) that discern measurement error from real change when monitoring patients with MASLD on a single scanner.
A flavonoid-rich diet is associated with lower risk and improved imaging biomarkers of nonalcoholic fatty liver disease: A prospective cohort study
Bell, W., et al. (2024)
The American Journal of Clinical Nutrition
Read Summary ▾
Higher dietary flavonoid intake was linked to lower risk of NAFLD. Participants with the highest flavonoid-rich diet scores had significantly lower cT1 values than those with the lowest scores. Tea, red wine, and sweet peppers were particularly associated with reduced cT1, suggesting flavonoid-rich diets may help lower risk for NAFLD.
Reference Range of Quantitative MRI Metrics Corrected T1 and Liver Fat Content in Children and Young Adults: Pooled Participant Analysis
Shumbayawonda, E., et al. (2024)
Children
Read Summary ▾
Multi-centre pooled analysis established reference ranges for cT1 and PDFF in healthy children and young adults. Values were normally distributed (median cT1 748 ms; PDFF 1.7%) and within the reported normal limits (<800 ms; <5%). Age comparisons showed clinically negligible cT1 and PDFF differences differences between paediatric and adult groups.
Fighting amyotrophic lateral sclerosis by protecting the liver? A prospective cohort study
Zhu, L., et al. (2024)
Annals of Neurology
Read Summary ▾
Multiparametric MRI, including cT1, was used to non-invasively monitor treatment response to lanifibranor in NASH. cT1 was significantly reduced after 24 weeks of treatment compared to placebo, indicating reduced hepatic fibroinflammation. Moreover, cT1 change was associated with histologic improvements in SAF activity score, supporting cT1 as a sensitive, non-invasive imaging biomarker for assessing therapeutic response in NASH
Gamma-glutamyl transferase: a potential biomarker for pancreas steatosis in patients with concurrent obesity, insulin resistance and metabolic dysfunction-associated steatotic liver disease
Chiyanika, C., et al. (2024)
Clinical obesity
Read Summary ▾
This study demonstrates clinical benefits of combining imaging markers with blood markers, such as GGT, in patients without a history of pancreatitis who have obesity and MASLD. Pairing LiverMultiScan with standard blood markers enables early identification and risk stratification of fatty pancreas in individuals with MASLD.
Liver magnetic resonance imaging, non-alcoholic fatty liver disease and metabolic syndrome risk in pre-pubertal Mexican boys
Alonso. D.C., et al. (2024)
Scientific Reports
Read Summary ▾
Multiparametric MRI assessed liver fat (PDFF) and fibroinflammation (cT1) in Hispanic prepubertal boys at risk for MASLD. Despite normal transaminases, mpMRI identified MASLD/MASH, with higher cT1/PDFF in those with metabolic risk factors. Elevated cT1 aligned with insulin resistance, supporting mpMRI, particularly cT1, for routine MASLD screening of high-risk pediatric groups.
Head-to-head comparison among FAST, MAST and multiparametric MRI-based new score in diagnosing at-risk MASH
Imajo, K., et al. (2024)
European Radiology
Read Summary ▾
Two new MRI-based scoring strategies—single-step MPcT (MRE+PDFF+cT1) and two-step M-PcT (LSM by MRE then PDFF with cT1)—were evaluated to detect at-risk MASH. M-PcT showed superior diagnostic accuracy over FAST, MAST, and MPcT. PDFF plus cT1 also performed strongly for diagnosing active MASH and severe hepatic inflammation, outperforming FAST and MAST scores.
Genetic risk amplifies lifestyle effects on hepatic steatosis and its progression: Insights from a population-based cohort
Zhang, X., et al. (2024)
Digestive and Liver Disease
Read Summary ▾
Genetic risk and lifestyle factors influence steatotic liver disease and cardiovascular events. Lifestyle effects were stronger in individuals with higher genetic risk, especially if overweight. Genetic factors, physical activity, and sleep duration interacted to influence cT1 and cardiovascular events. Targeted lifestyle interventions could be particularly effective in genetically susceptible populations.
Pilot feasibility study to determine the utility of direct access and quantitative magnetic resonance cholangiopancreatography (MRCP) in the assessment of suspected acute biliary or ductal gallstone presentations
Novak et al. (2024)
BMC Gastroenterology
Read Summary ▾
In suspected acute biliary or ductal gallstone presentations, first-line MRCP outperformed ultrasound-led standard care—delivering quicker, more cost-effective diagnosis and obstruction detection. MRCP+ also quantified gallbladder volume and cystic duct width, adding value for triage and management and supporting direct-access MRCP pathways.
Repeatability, Reproducibility, and Observer Variability of Cortical T1 Mapping for Renal Tissue Characterization
Nowak, M., et al. (2024)
Journal of Magnetic Resonance Imaging
Read Summary ▾
Kidney cortical T1 mapping is a highly repeatable and reproducible method across MRI manufacturers, field strengths, and operator conditions. The standardized methodological consistency paves the way for its adoption in multi-centre clinical trials.
Corrected T1 mapping in children and young adults with autoimmune liver disease: Correlation with histology
Trout, A. T., et al. (2023)
American Journal of Roentgenology
Read Summary ▾
Among children and young adults with autoimmune liver disease (AILD), cT1 mapping correlated strongly with histology, highlighting its ability to accurately assess liver inflammatory activity and fibrosis stage. Findings support cT1 as a useful, noninvasive tool that could reduce reliance on liver biopsy for assessing and monitoring AILD.
Quantitative imaging tests for non-alcoholic fatty liver disease: which, when and why
Dennis, A. et al. (2023)
Translational Gastroenterology and Hepatology
Read Summary ▾
This editorial reviews imaging modalities for NAFLD/NASH, endorsing PDFF for diagnosing NAFLD and positioning cT1 as the leading biomarker for NASH. It highlights cT1's utility for identifying patients with 'at-risk' NASH (with fibrosis) and for risk-stratifying patients with intermediate or indeterminate results on other guideline-recognized tests (AACE, AGA, DGVS).
Diagnosis and management of autoimmune hepatitis
Muratori, L., et al. (2023)
BMJ
Read Summary ▾
This state-of-the-art review highlights the clinical utility of cT1 in AIH diagnosis and management: it provides a quantitative, accurate, and reliable measurement of liver fibroinflammation, which correlates with histology, and predicts clinical outcomes. cT1 serves as a “virtual biopsy”, providing a “panoramic view” of liver tissue characteristics; it helps assess the heterogenous distribution of disease across the liver, supports monitoring, risk-stratification, and informs treatment-withdrawal decisions.
Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study
Dennis, A., et al. (2023)
Journal of the Royal Society of Medicine
Read Summary ▾
Among people recovering from acute COVID, multi-organ MRI (CoverScan) detected organ impairment in nearly 70% of patients at six months, persisting in over half at one year. Some were asymptomatic, yet impairment also tracked symptoms, especially high liver fat with severe breathlessness, supporting integration of multi-organ MRI into routine follow-up care.
Longitudinal changes in quantitative magnetic resonance imaging metrics in children and young adults with autoimmune liver disease
Mahalingam, N., et al. (2023)
Abdominal Radiology
Read Summary ▾
Longitudinal mpMRI in paediatric/young adult autoimmune liver disease showed individual, but not group, changes in cT1, MRE, and quantitative MRCP over two years. Changes in biliary MRCP+ metrics correlated with changes in liver stiffness (MRE) and fibro-inflammation (MRE, cT1), supporting personalized trajectory tracking and noninvasive monitoring.
Poor glycaemic control and ectopic fat deposition mediates the increased risk of non-alcoholic steatohepatitis in high-risk populations with type-2 diabetes: Insights from Bayesian-network modelling
Waddell, T., et al. (2023)
Frontiers in Endocrinology
Read Summary ▾
Using a Bayesian-network model, this study shows that in high-risk adults with type 2 diabetes, excess liver fat, poor glycaemic control, and excess visceral fat raise NASH risk by 31%, 22%, and 20%, respectively, with important implications for the development of targeted interventions to prevent NASH in high-risk populations.
The use of current knowledge and non-invasive testing modalities for predicting at-risk nonalcoholic steatohepatitis and assessing fibrosis
Kugelmas, M., et al. (2023)
Liver International
Read Summary ▾
This expert review proposes a clinical care pathway for suspected NAFLD, positioning cT1 as the key individual biomarker to risk-stratify patients and flag high-risk NASH to facilitate timely management. It further suggests that cT1 could replace or precede liver biopsy in all patients at intermediate/high risk of fibrosis, subject to hepatologist judgment.
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Tincopa, M. A., & Loomba, R. (2023)
Lancet Gastroenterology & Hepatology
Read Summary ▾
An expert review on advances in noninvasive tests for NAFLD recognizes cT1 as a validated tool for detecting NASH and at-risk NASH, correlating with NAS features and fibrosis. cT1 showed the highest rule-in specificity (90%) among the reviewed noninvasive tests for at-risk NASH at a cut-off of ≥ 875 ms.
Clonal haematopoiesis and risk of chronic liver disease.
Wong, W. J., et al. (2023)
Nature
Read Summary ▾
Across large population cohorts, clonal haematopoiesis of indeterminate potential was linked to higher risk of chronic liver disease, including NASH. Specifically, LiverMultiScan findings in UK Biobank participants revealed a higher prevalence of liver disease activity and liver fat in individuals with CHIP. LiverMultiScan may represent a modifiable risk factor for e.g. blood cancers and cardiovascular disease.
Right and left liver lobe biopsies by minilaparoscopy reveal clinically significant sampling error in staging and grading of autoimmune hepatitis
Johannes, H., et al. (2023)
Liver International
Read Summary ▾
An invasive minilaparoscopic biopsy of both liver lobes in AIH (AIH, AIH-PBC, and AIH-PSC) was more accurate for grading/staging disease activity than percutaneous biopsy, reflecting intrahepatic heterogeneity. Noninvasive LiverMultiScan cT1 demonstrated this heterogeneity, and its extent independently predicted disease flares, supporting multi-lobe sampling and cT1 for comprehensive assessment.
AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Rinella, M. E., et al. (2023)
Hepatology
Read Summary ▾
AASLD’s new practice guidance on the clinical management of NAFLD recommends sequentially integrating cT1 with other noninvasive tests for the identification and risk-stratification of patients with “at-risk” NASH in secondary/speciality care to facilitate better clinical management of these patients.
Bayesian-networks and imaging derived phenotypes highlight the role of fat deposition on risk of hospitalisation risk with COVID-19
Waddell, T., et al. (2023)
Frontiers in Bioinformatics
Read Summary ▾
Using Bayesian-network modeling, this study links body-fat distribution to COVID-19 hospitalization risk. Obesity increased risk versus normal weight; across all BMI groups, higher visceral fat and liver fat were associated with markedly greater hospitalization probability. Findings underscore multi-organ imaging and Bayesian models for understanding and stratifying COVID-19 risk.
Liver disease is a significant risk factor for cardiovascular outcomes
Roca-Fernandez, A., et al. (2023)
JHEP Reports
Read Summary ▾
Patients with increased liver disease activity (cT1) were more likely to develop cardiac conditions. Specifically, individuals with increased cT1 were ~30% more likely to be hospitalized due to a major adverse cardiovascular event. Findings suggest liver disease activity is a meaningful risk factor for heart disease and support cT1 for cardiovascular risk stratification.
To pay or not to pay for artificial intelligence applications in radiology
Lobig, F., et al. (2023)
NPJ Digital Medicine
Read Summary ▾
This review on the value of AI-supported digital applications in radiology describes LiverMultiScan as a tool detecting liver diseases with a high degree of accuracy compared to gold-standard liver biopsies, delivering comparable diagnostic information without the risks associated with an invasive procedure. It also reports that LiverMultiScan-derived parameters strongly predict clinical outcomes.
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Loomba, R., et al. (2023)
The New England Journal of Medicine
Read Summary ▾
In this phase 2b randomized controlled trial, treatment with FGF21 analogue pegozafermin, a novel therapy for treating NASH, led to improvements in liver fat and fibro-inflammation (liver disease activity) quantified by cT1 from baseline up to 24 weeks. These results support the advancement of pegozafermin into phase 3 development.
A low-energy total diet replacement program demonstrates a favorable safety profile and improves liver disease severity in nonalcoholic steatohepatitis
Koutoukidis, D. A., et al. (2023)
Obesity
Read Summary ▾
In NASH patients with obesity and fibrosis on a low-energy total diet replacement, LiverMultiScan cT1 detected significant reductions in liver disease activity. Compared to other NITs (CAP, MRE, VCTE), cT1 was the only consistent and reliable biomarker that captured change in liver disease severity, highlighting its utility for monitoring response to diet and lifestyle interventions.
Growth hormone administration improves nonalcoholic fatty liver disease in overweight/obesity: a randomized trial
Dichtel, L. E., et al. (2023)
The Journal of Clinical Endocrinology and Metabolism
Read Summary ▾
Growth hormone (GH) administration for six months showed promising results in ameliorating NAFLD in overweight and obese individuals. Specifically, cT1 measurements revealed significant improvements in liver disease activity, suggesting the potential of GH therapy as a novel approach for managing NAFLD in this population.
A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis
Vuppalanchi, R., et al. (2023)
JHEP Reports
Read Summary ▾
First validated prognostic model of clinical outcomes in PSC using a novel composite marker derived from quantitative MRCP metrics, bilirubin, and AST. It outperformed the traditional Mayo risk score in predicting transplant-free survival in patients with PSC, suggesting improved risk stratification and potential to improve clinical management.
Multiparametric magnetic resonance imaging and magnetic resonance elastography to evaluate the early effects of bariatric surgery on non-alcoholic liver disease
Tan, H. C., et al. (2023)
International Journal of Biomedical Imaging
Read Summary ▾
This first-of-its-kind study used LiverMultiScan and MRE to assess NAFLD in patients with morbid obesity over a six-month period following bariatric surgery. Liver disease activity (cT1) and liver fat (PDFF) significantly improved, but there was no change in liver stiffness (MRE). These results highlight LiverMultiScan’s utility for detecting early, clinically meaningful change during postoperative monitoring.
Cardiovascular imaging in the integrated assessment of metabolic health
Thomaides-Brears, H. B., et al. (2023)
Frontiers in Cardiovascular Medicine
Read Summary ▾
This editorial provides insights into the clinical utility of multi-modal imaging to study metabolic diseases with organ-specific and extra-organ manifestations requiring integrated care: “the multisystem nature of metabolic disease puts multiorgan imaging front and centre for integration of care to avoid putting patients at risk of the complications associated with biopsy”.
A snapshot of digital transformation in hepatology and rare liver disease related health care: A UK perspective
Ala, A., et al. (2023)
Mayo Clinic Proceedings: Digital Health
Read Summary ▾
An editorial on UK digital hepatology highlights the diagnostic and prognostic value of LiverMultiScan and MRCP+ in AILDs. LiverMultiScan’s cT1 has a prognostic value as it correlates with the risk of loss of biochemical remission in AIH. MRCP+ correlates with validated risk scoring systems and may improve diagnosis and prognostic models in primary PSC.
Liver investigation: Testing marker utility in steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol
Pavlides, M., et al. (2023)
Contemporary Clinical Trials
Read Summary ▾
The protocol for the LITMUS Imaging Study, a prospective multi-centre cohort study on adults with NAFLD, evaluating non-invasive imaging tools (LiverMultiScan, MR elastography, and ultrasound elastography) against liver histology as the reference standard. The goal is to identify the imaging tools that accurately stage the severity of liver fibrosis in people with NAFLD.
Reply to: Reassessing the causal relationship between liver diseases and cardiovascular outcomes and to: From Liver to Heart: Enhancing the Understanding of Cardiovascular Outcomes in the UK Biobank
Thomaides-Brears, H. B., et al. (2023)
Journal of Hepatology
Read Summary ▾
This opinion piece states that MASLD is an obesity-related condition that requires both imaging- and genetic-risk tools for a comprehensive picture of multi-organ associations. Without imaging data, genetic tools such as the Mendelian randomisation method alone may not provide clinically relevant information on liver health and cardiovascular risk in patients with MASLD.
Prognostic models and autoimmune liver diseases. Best Practice & Research
D’Amato, D., et al. (2023)
Clinical Gastroenterology
Read Summary ▾
Review of prognostic tools for the clinical management of patients with AILD. In AIH, LiverMultiScan cT1, an objective, accurate measure of fibro-inflammation, may be determinant in clinical decision-making and could substitute liver biopsy in follow-up. It also outlines the prognostic value of MRCP+ for PSC management.
Associations Between Quantitative MRI Metrics and Clinical Risk Scores in Children and Young Adults With Autoimmune Liver Disease
McCrary, J., et al. (2022)
American Journal of Roentgenology
Read Summary ▾
In a population of children and young adults with autoimmune liver disease (AILD), quantitative metrics from LiverMultiScan and MRCP+ were significantly associated with the MAYO and SCOPE risk scores and were independent predictors. These findings support multiparametric MRI using LiverMultiScan and MRCP+ as noninvasive tools for diagnosis risk stratification, and prognosis in AILD.
Technology-Enabled, Evidence-Driven, and Patient-Centered: The Way Forward for Regulating Software as a Medical Device
Carolan, J. E., et al., (2022)
JMIR Medical Informatics
Read Summary ▾
Opinion piece on regulating Artificial Intelligence (AI) and Machine Learning (ML) in software as a medical device (SaMD): advocates stronger technology literacy, clear evidence standards across the full product lifecycle, and continuous engagement of end-users to demonstrate safety and effectiveness—shifting SaMD oversight to be technology-enabled, evidence-driven, and patient-centred.
Pancreas MRI Segmentation Into Head, Body, and Tail Enables Regional Quantitative Analysis of Heterogeneous Disease
Bagur, A., et al. (2022)
Journal of Magnetic Resonance Imaging
Read Summary ▾
A novel MRI segmentation algorithm divides the pancreas into head, body, and tail, enabling regional quantification. It achieved excellent accuracy and reproducibility, supporting assessment of heterogeneous pancreatic disease and revealing subsegment-specific alterations in diabetes.
4D flow cardiovascular magnetic resonance derived energetics in the Fontan circulation correlate with exercise capacity and CMR-derived liver fibrosis/congestion
Rijnberg, F. M., et al. (2022)
Journal of Cardiovascular Magnetic Resonance
Read Summary ▾
In Fontan circulation, higher liver cT1 (fibrosis/congestion) correlated with impaired exercise capacity and adverse 4D blood flow measured with CMR. Findings link hepatic injury to hemodynamic inefficiency, supporting combined 4D flow CMR and LiverMultiScan for noninvasive risk assessment.
A quantitative magnetic resonance cholangiopancreatography metric of intrahepatic biliary dilatation severity detects high-risk primary sclerosing cholangitis
Selvaraj, E. A., et al. (2022)
Hepatology Communications
Read Summary ▾
In large-duct PSC, MRCP+ quantification of biliary dilatation identified high-risk patients and showed superior interobserver agreement when compared to qualitative MRCP, supporting MRCP+ for objective risk stratification and consistent reporting.
Magnetic resonance imaging metrics and the predictability of adverse outcomes in on-treatment Asian chronic hepatitis B
Hui, R. W., et al. (2022)
Journal of Gastroenterology and Hepatology
Read Summary ▾
In treated chronic hepatitis B with advanced fibrosis, liver iron quantified by LiverMultiScan predicted hepatocellular carcinoma (HCC) occurrence over 2 years. The same scan also assessed the pancreas, supporting a single, noninvasive workflow for longitudinal monitoring and prognostication in chronic hepatitis B.
Precision medicine for liver tumours with quantitative magnetic resonance imaging and whole genome sequencing (Precision1 trial): Study protocol for observational cohort study
Welsh, F., et al. (2022)
BMJ Open
Read Summary ▾
Study protocol for Precision1 trial: an observational radiogenomics cohort in liver tumours. Primary endpoint: proportion of patients whose management would change based on whole-genome sequencing. Secondary aims assess decision impact of LiverMultiScan- and Hepatica, and correlate quantitative MRI with genomic and histologic features to guide precision care.
Genetic variants of glycogen metabolism genes were associated with liver PDFF without increasing NAFLD risk
Yang, L., et al. (2022)
Frontiers in Genetics
Read Summary ▾
In a UK Biobank secondary analysis using LiverMultiScan, variants in glycogen-metabolism genes associated with MRI-PDFF were not linked to NAFLD risk, suggesting hepatic glycogen can bias PDFF and should be considered when interpreting MRI-based liver fat measurements.
The additive value of cardiovascular magnetic resonance in convalescent COVID-19 patients
Borlotti, A., et al. (2022)
Frontiers in Cardiovascular Medicine
Read Summary ▾
This review highlights CMR’s value in convalescent COVID-19, revealing frequent myocardial abnormalities months after infection. CMR also enabled the identification of multi-organ damage, indicating the importance of further investigation into the relationship between cardiac injury, ongoing symptoms, pre-existing risk factors, and damage to other organs.
A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population
Seidelin, A. S., et al. (2022)
Hepatology International
Read Summary ▾
A rare genetic variant (SLC30A10 p.Thr95Ile) is associated with elevated ALT and higher cT1 measured by LiverMultiScan, markers of liver fibro-inflammation, indicating the variant may increase liver-disease risk in the general population.
Quantitative MR in paediatric patients with Wilson Disease: A case series review
Janowski, K., et al. (2022)
Children
Read Summary ▾
In pediatric Wilson disease, LiverMultiScan’s cT1 and PDFF correlated with histological scores of fibrosis, inflammation, and steatosis, whereas ultrasound did not. MRCP+ identified dilatations in the biliary tree, not detected during the standard of care examination.
Greater ectopic fat deposition, liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetes
Waddell, T., et al. (2022)
Obesity
Read Summary ▾
UK Biobank analysis shows that people with type 2 diabetes have higher liver fat (PDFF) and fibro-inflammation (cT1) and lower skeletal muscle index than non-diabetic controls. In addition, LiverMultiScan detected greater liver damage in participants with T2D despite normal liver biochemistry (AST/ALT).
American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by AASLD
Cusi, K., et al. (2022)
Endocrine Practice
Read Summary ▾
AACE guideline provides evidence-based recommendations for NAFLD/NASH diagnosis and management in primary care and endocrinology. Its cirrhosis-prevention algorithm advises referring patients at indeterminate or high fibrosis risk for specialist evaluation using advanced noninvasive biomarkers, including cT1 (LiverMultiScan), to refine staging and guide care.
MRI in liver cirrhosis
Alzoubi, O., et al. (2022)
Portal Hypertension & Cirrhosis
Read Summary ▾
Review advocates streamlined, noninvasive pathways for cirrhosis assessment, replacing fragmented diagnostics and biopsies. LiverMultiScan cT1 is highlighted as a fast, fully noninvasive biomarker that can simplify clinical pathways, support diagnosis and screening of liver diseases, and reduce clinic burden.
AGA clinical practice update: Diagnosis and management of nonalcoholic fatty liver disease in lean individuals: Expert review
Long, M. T., et al. (2022)
Gastroenterology
Read Summary ▾
This American Gastroenterological Association (AGA) clinical practice update provides best practice advice on evidence-based approaches diagnosis, staging, and management of NAFLD in lean individuals. It recommends combining noninvasive biomarkers, such as cT1, with fibrosis tests (VCTE, MRE, and EFL) to identify and risk-stratify lean patients with NASH for most appropriate treatment.
Nonalcoholic fatty liver disease: Review of management for primary care providers
Basu, R., et al. (2022)
Mayo Clinic Proceedings
Read Summary ▾
This article reviews the evaluation, diagnosis, and management of adults with NAFLD/NASH in the primary care setting and endocrinology clinics. LiverMultiScan was cited as a potential tool for liver imaging and assessment to ensure prompt diagnosis of NAFLD/NASH in routine practice.
Quantitative magnetic resonance cholangiopancreatography is associated with severity and outcomes in Primary Sclerosing Cholangitis
Cazzagon, N., et al. (2022)
JHEP Reports
Read Summary ▾
Quantitative MRCP metrics in large-duct PSC correlated with established prognostic factors, ANALI (morphological scores based on MRCP images), liver stiffness (VCTE), and biochemical scores. Median duct diameter was associated with outcomes, underscoring quantitative MRCP’s prognostic value in patients with PSC.
LiverMultiScan as an alternative to liver biopsy to monitor autoimmune hepatitis in the National Health Service in England; an economic evaluation
Bajre, M., et al. (2022)
BMJ Open
Read Summary ▾
Early economic modelling from NHS England’s Oxford AHSN found LiverMultiScan to be a cost-effective, noninvasive alternative to painful, invasive surveillance liver biopsy for monitoring autoimmune hepatitis (AIH) across disease stages, saving up to £336,926, thus lowering NHS costs and procedure burden while enabling repeatable follow-up in routine care.
Cardiac impairment in long COVID 1-year post-SARS-CoV-2 infection
Roca-Fernandez, A., et al. (2022)
Open Heart
Read Summary ▾
CoverScan identified cardiac abnormalities in ~20%patients at 6 months, persisting in over half of those at 12 months following initial COVID-19 symptoms. Importantly, blood biomarkers were not as sensitive as MRI in identifying cardiac abnormalities, highlighting its utility in the clinical diagnosis and management of patients with multi-system conditions.
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis
Cristoferi, L., et al. (2022)
Digestive and Liver Disease
Read Summary ▾
Retrospective PSC cohort: quantitative MRCP (MRCP+) stricture count and spleen length independently associated with adverse events. MRCP+ outperformed manual radiological (ANALI) scores for risk stratification in PSC, supporting use for longitudinal monitoring and as a surrogate endpoint in clinical trials.
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
Ratziu, V., et al. (2022)
Journal of Hepatology
Read Summary ▾
Individuals with suspected fibrotic NASH treated with FXR agonist vonafexor showed a mean 80 ms absolute reduction in cT1 at week 12 from baseline, indicating a significant reduction in liver disease activity post-treatment. These findings suggest that vonafexor is a promising therapeutic for reversing liver fibro-inflammation in NASH.
Artificial intelligence for precision medicine in autoimmune liver disease
Gerussi, A., et al. (2022)
Frontiers in Immunology
Read Summary ▾
This review outlines the evidence on how AI and machine learning can address unmet needs in autoimmune liver diseases. In PSC, MRCP+ metrics can significantly improve the current diagnostic approach and risk prediction. In AIH, LiverMultiScan’s cT1 is described as an accurate non-invasive biomarker for risk stratification and monitoring, enabling precision-medicine workflows.
An international survey on patterns of practice in NAFLD and expectations for therapies—The POP‐NEXT project
Ratziu, V., et al. (2022)
Hepatology
Read Summary ▾
This international survey revealed major limitations in NAFLD/NASH management: delayed referrals, suboptimal screening, and absence of reliable tools for diagnose active steatohepatitis. Most respondents used multiple noninvasive fibrosis tests but had not used cT1, underscoring unmet need; LiverMultiScan cT1 could fill this diagnostic and monitoring gap.
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
Yip, T. C., et al. (2022)
Clinical and Molecular Hepatology
Read Summary ▾
This review highlights the importance of assessing liver inflammation in NAFLD with non-invasive biomarkers, especially in the drug development process, owing to the inaccuracies of liver biopsies. LiverMultiScan’s cT1 emerges as a robust biomarker that correlates with necroinflammation, fibrosis, and liver-related clinical outcomes, with fewer technical failures than ultrasound-based techniques.
NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned
Rasmussen, D. G. K., et al. (2022)
Journal of Hepatology
Read Summary ▾
This review distills LITMUS lessons on biomarker qualification to speed NAFLD/NASH drug development. cT1 (LiverMultiScan) was submitted to EMA/FDA for prognostic enrichment and now holds an FDA-accepted Biomarker Qualification Program, the first for a diagnostic enrichment biomarker in NASH trials, positioning cT1 to streamline recruitment and improve trial success.
Multi-organ imaging demonstrates the heart-brain-liver axis in UK Biobank participants
McCracken, C., et al. (2022)
Nature Communications
Read Summary ▾
This large UK Biobank study explored the relationship between heart, brain, and liver health. Individuals with poor liver health — quantified by cT1 mapping — were more likely to have brain abnormalities (e.g., cognitive decline and dementia) and poor heart health, underscoring the importance of multi-organ assessment when assessing an individual's overall health.
Quantitative multiparametric MRI allows safe surgical planning in patients undergoing liver resection for colorectal liver metastases: report of two patients
Sethi, P., et al. (2021)
BJR Case Reports
Read Summary ▾
Case report. Two colorectal liver metastasis resections with contrasting outcomes: retrospective pre-op Hepatica revealed high cT1 and PDFF in the patient who developed complications and prolonged stay, versus normal cT1 and PDFF in the short-stay case with no complications, indicating quantitative mpMRI can flag at-risk patients and guide safer surgical planning.
Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis
Dennis, A., et al. (2021)
Frontiers in Endocrinology
Read Summary ▾
The correlations between cT1 and PDFF with the histopathological hallmarks of NASH demonstrate the potential utility of both cT1 and PDFF as non-invasive biomarkers to detect a pharmacodynamic change in NASH, with cT1 showing superiority for detecting changes in inflammation and fibrosis, rather than liver fat alone.
Quantitative multiparametric MRI can aid NASH diagnosis in a Japanese cohort
Imajo, K., et al. (2021)
World Journal of Gastroenterology
Read Summary ▾
Comparative study in patients with historical diagnosis of NAFLD or suspected of NAFLD showed that cT1 and PDFF (LiverMultiScan) outperformed FibroScan, MRE, and SWE for identifying NASH, providing strong evidence for clinical adoption.
Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial
Amerikanou, C., et al. (2021)
Molecular Nutrition & Food Research
Read Summary ▾
LiverMultiScan’s cT1 was the primary endpoint in a multicenter, randomized, double-blind, placebo-controlled trial on the effect of Mastiha on liver inflammation and fibrosis. Over six months, cT1 decreased in participants with severe obesity, with no significant change on placebo.
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort
Harrison, S., et al. (2021)
Journal of Hepatology
Read Summary ▾
In asymptomatic, middle-aged U.S. adults, LiverMultiScan PDFF estimated NAFLD prevalence at 38% and biopsy-confirmed NASH prevalence was 14%. NASH associated with race, obesity, and diabetes. These findings underscore LiverMultiScan’s suitability for scalable population assessment to identify at-risk individuals and enrich NASH cohorts.
Hepatic steatosis rather than underlying obesity increases risk of infection and hospitalization for COVID-19
Roca-Fernandez, A., et al. (2021)
Frontiers in Medicine Gastroenterology
Read Summary ▾
In a large-scale UK Biobank study, hepatic steatosis, not obesity alone, predicted COVID-19 severity: obese individuals with elevated liver fat had ~5-fold higher hospitalization risk. LiverMultiScan can quantify liver fat to stratify risk and support public health policy, clinical triage, and targeted lifestyle interventions.
Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study
Dennis, A., et al. (2021)
BMJ Open
Read Summary ▾
Prospective community study of low-risk individuals with persistent post-COVID symptoms found widespread multi-organ involvement months after infection, affecting the heart, lungs, kidneys, pancreas and liver, with cardiac impairment more frequent in severe cases. These findings demonstrate feasibility and value of community-based, multiparametric assessment to guide management before and after infection.
Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort
Beyer, C., et al. (2021)
Plos One
Read Summary ▾
Biopsy-referenced comparison in NAFLD: LiverMultiScan PDFF performed well across all steatosis grades, while CAP (ultrasound) was adequate at lower fat levels but inferior to liver PDFF for moderate–severe steatosis. This supports MRI-PDFF as the preferred noninvasive metric when precise quantification is needed.
The effect of multiparametric magnetic resonance imaging in standard of care for non-alcoholic fatty liver disease: Protocol for a randomised control trial
Tonev, D., et al. (2021)
JMIR Research Protocols
Read Summary ▾
Protocol for RADIcAL1 study: a multi-centre, two-arm RCT across four European countries testing whether standardized mpMRI (LiverMultiScan) as a diagnostic test for suspected NAFLD in tertiary hepatology clinics is cost-effective versus current pathways (consultations and/or liver biopsy) in over 1072 adults.
Multiparametric MRI imaging, autoimmune hepatitis, and prediction of disease activity
Arndtz, K., et al. (2021)
Hepatology Communications
Read Summary ▾
In AIH, failure to maintain remission was associated with increased cT1, not FibroScan liver stiffness or ELF. Baseline cT1 also predicted subsequent biochemical relapse, whereas liver stiffness or ELF did not, supporting LiverMultiScan as a sensitive tool for risk stratification and earlier intervention.
Incidence of complications from percutaneous biopsy in chronic liver disease: a systematic review and meta-analysis
Thomaides-Brears, H., et al. (2021)
Digestive Diseases and Sciences
Read Summary ▾
Review of incidence of all complications and technical failure associated with percutaneous liver biopsy shows notable risk: major complications ~2% (mostly bleeding), minor ~10% (mostly pain), and ~1% technical failure. These findings support consideration of standardized, noninvasive alternatives for diagnosis and monitoring.
Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores
Ismail, M. F., et al. (2021)
European Radiology
Read Summary ▾
In PSC, MRCP+ quantitative duct metrics correlated with biochemical risk scores and MR elastography, with performance comparable to ANALI morphological scores. Combining MRCP+ with ANALI or with MRE improved association with the Mayo Risk Score, supporting integrated imaging and morphology for noninvasive risk assessment.
A 3D quantitative MRC modeling images detected case of intrahepatic biliary stricture diseases
Nanashima, A., et al. (2021)
Case Reports in Gastroenterology
Read Summary ▾
Case report using MRCP+ to convert MRCP into 3D biliary maps with quantitative metrics. Intrahepatic biliary stricture disease showed distinct ductal abnormalities versus controls. MRCP+ visualized and quantified strictures and dilatations across the entire tree at a glance, supporting earlier detection of subtle intrahepatic biliary disease.
Quantitative multiparametric MRI as a non-invasive stratification tool in children and adolescents with autoimmune liver disease
Janowski, K., et al. (2021)
Scientific Reports
Read Summary ▾
Paediatric AILD cohort with AIH and ASC underwent LiverMultiScan, MRCP+, biopsy, and blood-based liver function tests. Quantitative MRCP+ biliary metrics discriminated AIH from ASC, supporting noninvasive subtype stratification. Although cT1 did not differ between subtypes, LiverMultiScan provided parenchymal characterization and longitudinal monitoring, complementing MRCP+ for comprehensive assessment.
Patient understanding and experience of non-invasive imaging diagnostic techniques and the liver patient pathway
McKay, A., et al. (2021)
Journal of Patient-Reported Outcomes
Read Summary ▾
Automated Hepatica delivered accurate, repeatable liver and Couinaud segment volumes, matching expert radiologists while reducing inter-operator variability and measurement time. Standardized, deep-learning outputs support robust pre-surgical planning and comprehensive liver health assessment.
Non-alcoholic fatty liver disease: A patient guideline
Francque, S. M., et al. (2021)
JHEP Reports
Read Summary ▾
Multistakeholder NAFLD guideline—co-developed by patients, patient representatives, clinicians, and scientists—summarizes current care pathways. The emerging noninvasive tests section highlights multiparametric MRI as a promising tool to identify NASH with fibrosis, referencing Schaapman et al. (2020), which integrated LiverMultiScan cT1 into a clinical risk-assessment algorithm for NAFLD.
Repeatability and reproducibility of deep‑learning‑based liver volume and Couinaud segment volume measurement tool
Mojtahed, A., et al. (2021)
Abdominal Radiology
Read Summary ▾
Automated Hepatica delivered accurate, repeatable liver and Couinaud segment volumes, matching expert radiologists while reducing inter-operator variability and measurement time. Standardized, deep-learning outputs support robust pre-surgical planning and comprehensive liver health assessment.
Clinical utility of MRI biomarkers for identifying NASH patients at high risk of progression: A multi-center pooled data and meta-analysis
Andersson, A., et al. (2021)
Clinical Gastroenterology and Hepatology
Read Summary ▾
Multicenter, biopsy-paired NAFLD analysis shows MRI PDFF and cT1 accurately identify NASH; cT1 better pinpoints patients at high risk of progression than liver fat alone. The data supports cT1 as a noninvasive biomarker for triage, risk stratification, and trial enrichment.
Comparison of quantitative 3D magnetic resonance cholangiography measurements obtained using three different image acquisition methods
Mahalingam, N., et al. (2021)
Abdominal Radiology
Read Summary ▾
This study compares quantitative biliary measurements obtained using MRCP+ and three different MRCP acquisition methods, showing that MRCP with compressed sensing to reduce acquisition time produced comparable biliary diameter metrics and global duct quantification to clinically indicated MRCP.
Improved pathology reporting in NAFLD/NASH for clinical trials
Langford, C. R., et al. (2021)
Journal of Clinical Pathology
Read Summary ▾
Synoptic reporting provides a comprehensive and structured format, which results in a complete assessment of liver disease. This opinion piece proposes using synoptic reporting, in place of the existing narrative style, in liver biopsies for NAFLD and NASH clinical trials to improve trial success rates and accelerate drug development.
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: diagnostic and mechanistic relevance
Johnson, K., et al. (2021)
JHEP Reports
Read Summary ▾
In LITMUS, serum miRNA profiling identified elevated miR-193a-5p with worsening fibrosis and higher NAS/SAF scores, replicated in an independent cohort. Findings support circulating miRNAs, especially miR-193a-5p, as noninvasive biomarkers to detect advanced NAFLD without a liver biopsy.
Safety, tolerability, and biologic activity of AXA1125 and AXA1957 in subjects with nonalcoholic fatty liver disease
Harrison, S. A., et al. (2021)
The American Journal of Gastroenterology
Read Summary ▾
cT1 (LiverMultiScan) was significantly reduced after 16 weeks of novel NASH treatment, AXA1125, versus placebo, with twice as many patients achieving a reduction of cT1 ≥ 80 ms, previously linked to improved histopathological outcomes. AXA1125 also reduced liver fat (MRI-PDFF) and improved metabolic and fibro-inflammatory markers (HOMA-IR, ALT, CK18-M65, Pro-C3).
Associations between MRI T1 mapping, liver stiffness, quantitative MRCP, and laboratory biomarkers in children and young adults with autoimmune liver disease
Mahalingam, N., et al. (2021)
Abdominal Radiology
Read Summary ▾
In paediatric and young adult with autoimmune liver disease AILD, multiparametric MRI (LiverMultiScan) and MRCP+ showed robust associations with laboratory markers. cT1 correlated with markers of liver disease activity, and cT1 IQR appeared less confounded than MRE. MRCP+ biliary metrics discriminated AIH from PSC/ASC, supporting combined imaging for noninvasive stratification and monitoring.
Nutrition and nonalcoholic fatty liver disease – Current perspectives
Chakravarthy, M. V., et al. (2020)
Gastroenterology Clinics
Read Summary ▾
Nutrition-focused review of NAFLD/NASH: how macro- and micronutrients shape disease biology and overlap with drug targets. Lifestyle modification remains first-line therapy. The review also offers a practical dietary framework to integrate with medical management and address cardiometabolic risk.
Quantitative MRCP Imaging: Accuracy, repeatability, reproducibility, and cohort-derived normative ranges
Goldfinger, M., et al. (2020)
Journal of Magnetic Resonance Imaging
Read Summary ▾
Quantitative MRCP (MRCP+) is an accurate, repeatable and reproducible method. Compared with qualitative MRCP, MRCP+ reduces subjectivity, quantifies duct diameters along the biliary tree, and detects candidate strictures and dilatations with high sensitivity and specificity. Quantitative MRCP improves upon the current “gold standard” of noninvasive imaging of the biliary tree.
NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis
Harrison, S. A., et al. (2020)
Journal of Hepatology
Read Summary ▾
Results from a Phase 2 NASH trial showing that LiverMultiScan (cT1) can detect drug efficacy in as little as 6 weeks to serve as an early go/no-go signal. cT1 differentiated responders, tracked changes, and correlated with histology and serum biomarkers, enabling sensitive, non-invasive longitudinal monitoring.
Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis
Parisinos, C. A., et al. (2020)
Journal of Hepatology
Read Summary ▾
GWAS study of cT1 (LiverMultiScan) in 14,440 UK Biobank participants identified SLC39A as a genetic variant associated with fibro-inflammatory liver disease. Findings highlight SLC39A8 as a potential drug target and reinforce cT1 as a genetics-informed biomarker.
Relationship between magnetic resonance imaging spleen T1 relaxation and other radiologic and clinical biomarkers of liver fibrosis in children and young adults with autoimmune liver disease
Dillman, J. R., et al. (2020)
Abdominal Radiology
Read Summary ▾
In pediatric and young adult autoimmune liver disease, splenic T1 was associated with radiologic and clinical fibrosis markers, including radiologic portal hypertension.
Comparison of liver T1 relaxation times without and with iron correction in pediatric autoimmune liver disease
Dillman, J. R., et al. (2020)
Pediatric Radiology
Read Summary ▾
In pediatric autoimmune liver disease, LiverMultiScan showed an excellent positive correlation between liver native T1 and iron-corrected cT1 in a cross-sectional study, suggesting limited iron confounding in this cohort.
New boundaries of liver imaging: from morphology to function
Cruz, M., et al. (2020)
European Journal of Internal Medicine
Read Summary ▾
Modern liver imaging pairs structure with function: techniques such as multiparametric MRI deliver noninvasive surrogate biomarkers for focal and diffuse disease, supporting diagnosis, staging, and treatment monitoring.
Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes
Hydes, T. J., et al. (2020)
Diabetic Medicine
Read Summary ▾
This review discusses bidirectional links between NAFLD and type 2 diabetes, recommends MAFLD nomenclature, and details screening with noninvasive tests/imaging for advanced fibrosis. Outlines lifestyle, glucose-lowering drugs, and metabolic surgery, noting extra-hepatic risks and medication considerations.
Pancreas Segmentation-Derived Biomarkers: Volume and Shape Metrics in the UK Biobank Imaging Study
Bagur, A. T., et al. (2020)
Medical Image Understanding and Analysis
Read Summary ▾
A new technique for group-wise registration and manifold learning of pancreas images could be used for automated quality control and to determine abnormal pancreas morphology, which might reflect different patterns of fat infiltration.
Segmentation of the Biliary Tree from MRCP Images via the Monogenic Signal
Ralli, G. P., et al. (2020)
Medical Image Understanding and Analysis
Read Summary ▾
Monogenic signal–based MRCP segmentation accurately detects bile ducts and quantifies duct diameters, outperforming the widely used Frangi vesselness filter—enhancing automated biliary tree delineation for quantitative MRCP.
Segmenting Hepatocellular Carcinoma in Multi-phase CT
Vogt, N., et al. (2020)
Medical Image Understanding and Analysis
Read Summary ▾
Radiology-inspired machine learning method combining complementary tumour characteristics from both arterial phase and portal venous phase CT images offers improved accuracy in automatically delineating liver lesions.
Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease
Jayaswal, A., et al. (2020)
Liver International
Read Summary ▾
LiverMultiScan’s noninvasive MRI biomarker cT1 predicts clinical outcomes in liver disease patients, outperforming FibroScan’s transient elastography and FIB-4, with performance comparable to invasive liver biopsy. After accounting for high technical failure rates, FibroScan lost prognostic value—underscoring cT1 as a robust, noninvasive risk-stratification biomarker.
Multiparametric MR mapping in clinical decision-making for diffuse liver disease
Thomaides-Brears, H. B., et al. (2020)
Abdominal Radiology
Read Summary ▾
This review of techniques for clinical decision-making in diffuse liver disease highlights the advantages of cT1 (LiverMultiScan), showing superior NASH diagnostic performance compared with MRE, which requires additional hardware and is confounded by even mild iron overload and inflammation, and compared with DWI, which currently lacks standardization.
Ethnic Differences in body fat deposition and liver fat content in two UK-based cohorts
Alenaini, W., et al. (2020)
Obesity
Read Summary ▾
This study across two independent UK cohorts found limited ethnic differences in body-fat depot distribution linked to metabolic disease, suggesting that alternative mechanisms should be investigated. In the UK Biobank cohort, LiverMultiScan measured PDFF using a standardized workflow, scalable for large populations and enabling consistent, cross-site comparisons.
Multiparametric MRI in patients with nonalcoholic fatty liver disease
Schaapman, J. J., et al. (2020)
Journal of Magnetic Resonance Imaging
Read Summary ▾
This review contains the first European guidance on multiparametric MRI, including cT1, for suspected NAFLD: outlines how to assess fibrosis and inflammation risk and suggests how clinical management and treatment monitoring can be improved.
rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis
Teo, K., et al. (2020)
Journal of Hepatology
Read Summary ▾
Meta-analysis of more than 42 studies, including UK Biobank and cohorts with LiverMultiScan fat quantification confirms that a common genetic variant is a risk factor for presence and severity of NAFLD in individuals of European descent.
Multiparametric MRI as a non-invasive monitoring tool for children with autoimmune hepatitis
Janowski, K., et al. (2020)
Journal of Pediatric Gastroenterology and Nutrition
Read Summary ▾
In paediatric autoimmune hepatitis (AIH), LiverMultiScan’s cT1 correlated with biochemical markers of disease severity and detected active disease even when routine labs were normal. These findings support cT1 as a sensitive, non-invasive tool to aid monitoring in AIH and guide timely management.
A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis
Dennis, A., et al. (2020)
Scientific Reports
Read Summary ▾
In biopsy-confirmed NAFLD, LiverMultiScan’s cT1, blood-based AST, GGT, and fasting glucose predicted significant fibrosis. The combined cTAG score (cT1+AST+glucose) outperformed individual markers, highlighting its utility for screening patients prior to biopsy to identify those suitable for NASH clinical trial enrolment.
Serum Matrix Metalloproteinase 7 Is a Diagnostic Biomarker of Biliary Injury and Fibrosis in Pediatric Autoimmune Liver Disease
Lam, S., et al. (2020)
Hepatology Communications
Read Summary ▾
Serum MMP7 was evaluated as a biomarker for sclerosing cholangitis in paediatric patients with autoimmune liver disease (AILD). Higher sMMP7 levels associated with histologic bile duct injury and hepatic fibrosis, and on MRCP+ correlated with the number of biliary dilatations and strictures, supporting sMMP7 as a noninvasive indicator of ductal disease severity.
Liver cT1 decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus
Jayaswal, A., et al. (2020)
Abdominal Radiology
Read Summary ▾
LiverMultiScan’s cT1 decreased in patients with chronic hepatitis C virus (HCV) undergoing direct-acting antiviral therapy. The fast reduction in cT1 is consistent with reduced inflammation rather than fibrosis regression, supporting LiverMultiScan as a sensitive biomarker for treatment monitoring.
Magnetic resonance imaging predicts individual future liver performance after liver resection for cancer
Mole, D. J., et al. (2020)
PLOS ONE
Read Summary ▾
This study highlights the utility of Hepatica for identifying patients at increased risk of poor post-operative liver performance and longer hospital stay. Pre-operative cT1 predicts length of post-operative hospital stay and has potential to inform the individualised risk assessment and surgical decision-making for liver cancer surgery.
Diagnostic performance of quantitative magnetic resonance imaging biomarkers for predicting portal hypertension in children and young adults with autoimmune liver disease
Dillman, J., et al. (2019)
Pediatric Radiology
Read Summary ▾
Evaluates the utility of quantitative MRI biomarkers including elastography and cT1 mapping for predicting portal hypertension in a paediatric population. Liver and spleen stiffness, along with liver cT1, predict radiologic portal hypertension with good accuracy.
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L. et al. (2019)
Reviews in Basic and Clinical Gasteroenterology and Hepatology
Read Summary ▾
Review of non-invasive methods for assessing liver disease in NAFLD and how they could be used in clinical practice. Highlights the key issues of differentiating NASH from simple steatosis and identifying advanced fibrosis.
Magnitude-intrinsic water–fat ambiguity can be resolved with multipeak fat modeling and a multipoint search method
Bagur, A., et al. (2019)
Magnetic Resonance in Medicine
Read Summary ▾
Technical validation of LiverMultiScan technique (MAGO) for measurement of liver fat: MAGO showed excellent accuracy and reproducibility across MR vendors at different field strengths. Technically challenging cases were processable with MAGO, demonstrating robustness of the technique.
Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration
Wilman, H. R., et al. (2019)
Journal of Hepatology
Read Summary ▾
Three genetic variants that are linked to an increased risk of developing higher liver iron content were identified. Mendelian randomisation analysis provided evidence that higher central obesity plays a causal role in increased liver iron content.
Differentiating pediatric autoimmune liver diseases by quantitative magnetic resonance cholangiopancreatography
Gilligan, L. A., et al. (2019)
Abdominal Radiology
Read Summary ▾
Quantitative MRCP+ outperformed serum biochemistry in differentiating paediatric PSC/ASC from AIH: all but one MRCP+ parameter significantly differed between cohorts and predicted diagnosis, whereas no laboratory values were significantly different between cohorts. Findings highlight MRCP+ as a useful non-invasive tool providing multiple imaging biomarkers of autoimmune liver disease.
Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: A proof of concept study
Levick, C., et al. (2019)
PLOS ONE
Read Summary ▾
Proof-of-concept evaluation of multi-parametric MRI (LiverMultiScan) for non-invasive assessment of portal hypertension. Spleen cT1 emerged as a promising marker of portal pressure, outperforming established non-invasive scores and indicating potential for safer, more accurate monitoring.
Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes
Marjot, T., et al. (2019)
JGH Open
Read Summary ▾
LiverMultiScan’s cT1 was used alongside other technologies to identify new indications for existing type 2 diabetes drugs. cT1 confirmed an absence of treatment effect of dapagliflozin in this small NAFLD cohort.
Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver
Bachtiar, V., et al. (2019)
PLoS One
Read Summary ▾
Technical validation of LiverMultiScan demonstrating good reproducibility and repeatability for quantifying liver tissue characteristics across different MR vendors and field strengths. Standardized biomarkers with low variability, like LiverMultiScan, are crucial for reliable readings in longitudinal monitoring in multicentre clinical trials.
Multiparametric magnetic resonance imaging for early detection of diffuse liver disease
Breen, D. (2018)
Biomarkers in Medicine
Read Summary ▾
From a radiologist’s perspective, LiverMultiScan delivers early, non-invasive detection of diffuse liver disease with reproducible, decision-ready biomarkers. It reduces biopsies, outperforms other non-invasive tests, and drives cost-effective patient stratification and monitoring, helping providers act sooner and health systems save more.
Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study
McDonald, N., et al. (2018)
Scientific Reports
Read Summary ▾
LiverMultiScan achieved a 98.1% technical success rate—including in obesity—outperforming transient elastography (85%). It showed excellent repeatability and reproducibility and strong diagnostic accuracy for hepatic fibroinflammation, fat, and iron.
Non-invasive assessment of liver disease in rats using multiparametric magnetic resonance imaging: A feasibility study
Hoy, A. M., et al. (2018)
Biology Open
Read Summary ▾
LiverMultiScan accurately quantified levels of hepatic fibroinflammation, fat, and iron in preclinical models.
Reference range of liver corrected T1 values in a population at low risk for fatty liver disease: a UK Biobank sub-study with an appendix of interesting cases
Mojtahed, A., et al. (2018)
Abdominal Radiology
Read Summary ▾
This study establishes cT1 reference ranges in a large, low-risk UK Biobank cohort, which serves as a benchmark for normal liver, aids clinical interpretation and study design, reinforcing cT1 as a reliable quantitative biomarker for liver health and disease.
Current status of imaging in nonalcoholic fatty liver disease
Li, Q., et al. (2018)
World Journal of Hepatology
Read Summary ▾
Review of imaging methods for NAFLD risk stratification and management, including multiparametric MRI (LiverMultiScan), MR Elastography and Ultrasound Elastography.
Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 controlled study
Harrison, S., et al. (2018)
PloS One
Read Summary ▾
cT1 showed superior reproducibility (CoV 3.1%) compared to the other non-invasive liver tests used in this NASH clinical trial: magnetic resonance elastography (MRE, CoV 11%) and transient elastography (TE, 40%). This underscores utility of cT1 as a sensitive, reliable marker for monitoring longitudinal change in NASH patients.
Study Protocol: HepaT1ca – An observational clinical cohort study to quantify liver health in surgical candidates for liver malignancies
Mole, D. J., et al. (2018)
BMC Cancer
Read Summary ▾
This ongoing trial will refine the technology and clinical application of LiverMultiScan in quantifying pre-existing liver health and predicting post-intervention outcomes following liver resection in cancer.
Validation of a standardized method for liver fat and T2* quantification
Hutton, C., et al. (2018)
PloS One
Read Summary ▾
Technical validation of the LiverMultiScan technique (LMS IDEAL) for liver fat quantification: high accuracy and excellent reproducibility across major MR vendors and field strengths and over a wide range of values. Perspectum is the only imaging provider with the IDEAL technique standardized across vendors, enabling consistent, scalable multi-site deployment.
Mapping tissue water T(1) in the liver using the MOLLI T(1) method in the presence of fat, iron and B(0) inhomogeneity
Mozes, F. E., et al. (2018)
NMR in Biomedicine
Read Summary ▾
Describes a method for computing a “water T1” by correcting the MOLLI T1 for the confounding influence of iron, fat, and frequency offsets. This has the potential to improve the characterisation of fibro-inflammatory liver disease.
Measurement of liver iron by magnetic resonance imaging in the UK Biobank population
McKay, A., et al. (2018)
PloS One
Read Summary ▾
LiverMultiScan was used to quantify hepatic iron levels in 9,108 UK Biobank participants, demonstrating feasibility for large-scale, non-invasive population assessment of liver iron with this technique.
Characterisation of liver fat in the UK Biobank cohort
Wilman, H. R., et al. (2017)
PloS One
Read Summary ▾
LiverMultiScan was used to measure hepatic fat in ~5,000 participants in the UK Biobank with a success rate of 96.8% and acquisition time of 3 minutes, enabling cost-effective population screening at scale.
Interobserver variability in histologic evaluation of liver fibrosis using categorical and quantitative scores
Pavlides, M., et al. (2017)
American Journal of Clinical Pathology
Read Summary ▾
Assessment of liver fibrosis by digital imaging analysis of Collagen Proportionate Area (CPA) followed by visual assessment of CPA is more robust than visual analysis alone with improved agreement between pathologists.
Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease
Eddowes, P., et al. (2017)
Alimentary Pharmacology & Therapeutics
Read Summary ▾
LiverMultiScan accurately identified patients with steatosis, stratified those with NASH, and reliably excluded clinically significant liver disease, with superior negative predictive value (83.3%) vs. transient elastography (42.9%) and ELF (57.1%). For NAFLD risk stratification, LiverMultiScan was cost-effective and, when combined with transient elastography, delivered the lowest cost per correct diagnosis.
Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease
Pavlides, M., et al. (2016)
Journal of Hepatology
Read Summary ▾
LiverMultiScan demonstrated 100% negative predictive value for liver-related clinical outcomes, in patients monitored for up to 40 months. This holds prognostic potential for stratification of patients to facilitate clinical management and clinical trials.
Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes
Levelt, E., et al. (2016)
Journal of the American College of Cardiology
Read Summary ▾
LiverMultiScan showed elevated hepatic fibroinflammatory and fat levels in asymptomatic patients with type 2 diabetes, suggesting significant NAFLD and NASH. This highlights an urgent need – and potential application of the technology – in screening, staging and monitoring diabetic liver disease.
A model for hepatic fibrosis: the competing effects of cell loss and iron on shortened modified Look-Locker inversion recovery T1 (shMOLLI-T1) in the liver
Tunnicliffe, E. M., et al. (2016)
Journal of Magnetic Resonance Imaging
Read Summary ▾
Validation of the technology underpinning cT1: iron correction of liver T1 values produces more accurate measurement of hepatic fibroinflammation.
Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging
Blake, L., et al. (2016)
BMJ Open
Read Summary ▾
The inclusion of LiverMultiScan, either as an adjunct to or replacement of transient elastography (TE) in the diagnostic pathway of NAFLD, leads to cost savings for the NHS by reducing the number of liver biopsies required. When used in place of TE and liver biopsy, LiverMultiScan remains cost-effective up to a price of £672.
Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity
Pavlides, M., et al. (2016)
Liver International
Read Summary ▾
LiverMultiScan had a higher success rate in NAFLD patients (95%) compared to transient elastography (59%), and showed high accuracy for the diagnosis of NASH and ballooning. This demonstrates potential application in patient management and supports use as a surrogate endpoint in clinical trials.
Evidence of a Direct Effect of Myocardial Steatosis on LV Hypertrophy and Diastolic Dysfunction in Adult and Adolescent Obesity
Banerjee, R., et al. (2015)
JACC: Cardiovascular Imaging
Read Summary ▾
Proton MRS (1H-MRS) and cardiac MRI showed that even in the absence of other comorbidities, adult and childhood obesity is related to cardiac steatosis. Higher myocardial triglyceride content relates to diastolic dysfunction, stronger in males. The findings suggest that cardiac steatosis occurs early in obesity and significantly affects childhood.
Menopausal Status and Abdominal Obesity Are Significant Determinants of Hepatic Lipid Metabolism in Women
Hodson, L., et al. (2015)
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Read Summary ▾
First study to report that abdominal obesity in women, and post-menopausal weight gain, are major drivers of very low-density lipoprotein secretion, which may increase risk of cardiovascular disease.
Investigating a liver fat: arterial stiffening pathway in adult and childhood obesity
Rider, O., et al. (2015)
Arteriosclerosis, Thrombosis, and Vascular Biology
Read Summary ▾
Hepatic fat measured by 1H-MRS is related to increased aortic stiffness in both adults and children. Hepatic fat content is a potential therapeutic target to treat the elevated vascular risk in obesity, which requires reliable biomarkers for monitoring response to treatment.
Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher propensity for NAFLD in men
Pramfalk, C., et al. (2015)
Journal of Clinical Endocrinology and Metabolism
Read Summary ▾
Men were observed to have a higher prevalence and greater risk of NAFLD compared with women despite similar levels of hepatic fat content. This is potentially driven by sex- specific differences in fatty acid metabolism.
Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease
Banerjee, R., et al. (2013)
Journal of Hepatology
Read Summary ▾
First clinical validation showing that LiverMultiScan accurately stages chronic liver disease and has high diagnostic accuracy for assessment of liver fibrosis, steatosis and haemosiderosis. This is the first demonstration of a non-invasive test differentiating early stages of fibrosis from normal liver with high diagnostic accuracy.
Rapid quantification of myocardial lipid content in humans using single breath hold 1H MRS at 3 Tesla
Rial, B., et al. (2011)
Magnetic Resonance in Medicine
Read Summary ▾
Cardiac lipid levels measured using rapid single breath-hold 1H-magnetic resonance spectroscopy (1H-MRS) at 3T shows excellent correlation with results obtained by averaging over seven multiple breath-holds. This study demonstrates that single breath-hold 1H-MRS at 3T is a rapid and reliable method to quantify myocardial lipids.
A fasting-mimicking diet programme reduces liver fat and liver inflammation/fibrosis measured by magnetic resonance imaging in patients with type 2 diabetes. A fasting-mimicking diet programme reduces liver fat and liver inflammation/fibrosis measured by Magnetic Resonance Imaging in patients with type 2 diabetes
Van Den Burg., et al. (0005)
Clinical Nutrition
Read Summary ▾
A 12-month fasting-mimicking diet programme reduced liver fat (MRI-PDFF) and inflammation/fibrosis (cT1) in type 2 diabetes patients. Improvements in cT1 and PDFF correlated with reductions in HbA1c, fasting glucose, triglycerides, weight, and total cholesterol. This dietary approach shows promise as an adjunct therapy to standard diabetes care.
Quantitative Magnetic Resonance Imaging to Aid Clinical Decision Making in Autoimmune Hepatitis
Heneghan, M. A., et al. (0002)
EClinicalMedicine
Read Summary ▾
First-of-its-kind evaluation in biopsy-proven AIH: LiverMultiScan’s cT1 increases clinician confidence and influences management by improving disease characterization and early detection of patients in biochemical remission with undetected, active sub-clinical disease at a high risk of relapse, compared to VCTE and serum biomarkers alone.